A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Jan 2016
At a glance
- Drugs MK 2206 (Primary)
- Indications Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 28 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 04 Oct 2012 New source identified and integrated (University of Southern California Norris Comprehensive Cancer Center; SWOG-S1005).
- 17 May 2012 Planned end date changed from 1 Jul 2011 to 1 May 2014 as reported by ClinicalTrials.gov.